Inovio presenta aprobación acelerada de VOCERYQ por la FDA para adultos con RRP
- Inovio obtiene la aprobación acelerada de la FDA para VOCERYQ como tratamiento de adultos con RRP.
- VOCERYQ es el primer producto de la empresa; reduce la necesidad de cirugía al actuar sobre la causa viral de la enfermedad.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.